Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2008-11-14
2010-02-16
Allen, Marianne P (Department: 1647)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S320100, C435S325000, C536S023500
Reexamination Certificate
active
07662586
ABSTRACT:
Synthetic polynucleotides encoding human HER2
eu or a truncated form thereof, are provided, the synthetic polynucleotides being codon-optimized for expression in a human cellular environment. The gene encoding hHER2 is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the hHER2 tumor-associated antigen, wherein aberrant hHER2 expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying codon-optimized human HER2 and codon-optimized truncated HER2, and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
REFERENCES:
patent: 5837523 (1998-11-01), Greene et al.
patent: 5846538 (1998-12-01), Cheever et al.
patent: 5869445 (1999-02-01), Cheever et al.
patent: 6127344 (2000-10-01), Amici et al.
patent: WO02/22080 (2002-03-01), None
patent: WO2004/041065 (2004-05-01), None
patent: WO2004/061105 (2004-07-01), None
Bargmann, et al., “The neu oncogene encodes an epidermal growth factor receptor-related protein”, Nature, vol. 319, Jan. 16, 1986, pp. 226-230.
Ben-Levy, et al., “A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway”, EMBO Journal, vol. 13, No. 14, pp. 3302-3311, 1994.
Coussens, et al., “Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene”, Science, vol. 230, pp. 1132-1139, Dec. 6, 1985.
Disbrow, et al., “Codon optimization of the HPV-16 E5 gene enhances protein expression”, Virology, vol. 311, pp. 105-114, 2003.
Disis, et al., “Cancer Vaccines Targeting the Her2
eu Oncogenic Protein”, Seminars in Oncology, vol. 28, No. 6, Suppl. 18, Dec. 2001, pp. 12-20.
Disis, et al., “Generation of T-Cell Immunity to the Her-2
eu Protein After Active Immunication With Her-2
eu Peptide-Based Vaccines”, Journal of Clinical Oncology, vol. 20, No. 11, Jun. 1, 2002, pp. 2624-2632.
Disis, et al., “Her-2
eu Protein: A Target for Antigen-Specific Imunotherapy of Human Cancer”, Advances in Cancer Research, vol. 71, pp. 343-371, 1997.
Disis, et al., “Oncogene proteins as tumor antigens”, Current Opinion in Immunology, vol. 8, 1996, pp. 637-642.
Fisk, et al., “Identification of Naturally Processed Human Ovarian Peptides Recognized by Tumor-Associated CD8+ Cytotoxic T Lymphocytes”, Cancer Research, vol. 57, pp. 87-93, Jan. 1, 1997.
Foy, et al., “Vaccination with Her-2
eu DNA or protein subunits protects against growth of a Her-2
eu-expressing murine tumor”, Vaccine, vol. 19, pp. 2598-2606, 2001.
Gallo, et al., “Xenogeneic Immunization in Mice Using HER2 DNA Delivered by an Adenoviral Vector”, Int. J. Cancer, vol. 113, pp. 67-77, 2004.
Ikemura, “Codon Usage and tRNA Content in Unicellular and Multicellular Organisms”, Mol Biol. Evol. vol. 2, No. 1, pp. 13-34, 1985.
Ioannides, et al., “Cytotixic T Cells Isolated from Ovarian Malignant Ascites Recognize a Peptide Derived from the Her-2
eu Proto-oncogene”, Cellular Immunology, vol. 151, pp. 225-235, 1993.
King, et al., “Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma”, Science, vol. 229, No. 4717, pp. 974-976, 1985.
Klapper, et al., “Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors”, Adv. Cancer Res., vol. 77, pp. 25-79, 2000.
Leder, et al., “Enhancement of Capsid Gene Expression: Preparing the Human Papillomavirus Type 16 Major Structural Gene L1 for DNA Vaccination Purposes”, J. of Virol., vol. 75, No. 19, pp. 9201-9209, Oct. 2001.
Lustgarten, et al., “Identification of Her-2/Neu CTL Epitopes Using Double Transgenic Mice Expressing HLA-A2.1 and Human CD.8”, Human Immunology, vol. 52, pp. 109-118, 1997.
Messerle, et al., “NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant”, Mol. and Cell. Endo., vol. 105, pp. 1-10, 1994.
Montgomery, et al., “Heterologous and Homologous Protection Against Influenza A by DNA Vaccination: Optimization of DNA Vectors”, DNA and Cell Biology, vol. 13, No. 9, pp. 777-783, 1993.
Nakamura, et al., “Codon usage tabulated from the international DNA sequence databases: Its status 1999”, Nucleic Acids Research, vol. 27, No. 1, pp. 292, 1999.
Peoples, et al., “T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal frowth factor-like growth factor and basic fibroblast growth factor: A potential pathologic role”, PNAS, USA, vol. 92, pp. 6547-6551, 1995.
Press, et al., “Expression of the HER-2
eu proto-oncogene in normal human adult and fetal tissues”, Oncogene, vol. 5, pp. 953-962, 1990.
Shih, et al., “Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts”, Nature, vol. 290, pp. 261-264, Mar. 19, 1981.
Slamon, et al., “Studies of the HER-2
eu Proto-oncogene in Human Breast and Ovarian Cancer”, Science, vol. 244, 707-712, May 12, 1989.
Slichenmyer, et al., “Anticancer Therapy Targeting the ErbB Family of Receptor Tyrosine Kinases”, Seminars in Oncology, vol. 28, No. 5, Suppl. 16, Oct. 2001, pp. 67-79.
Yamamoto, et al., “Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor”, Nature, vol. 319, pp. 230-234, Jan. 22, 1986.
Yarden, et al., “Biology of HER2 and Its Importance in Breast Cancer”, Oncology, vol. 61 (Suppl. 2), pp. 1-13, 2001.
Yoshino, et al., “HER2
eu-derived Peptides Are Shared Antigens among Human Non-Small Cell Lung Cancer and Ovarian Cancer”, Cancer Research, vol. 54, pp. 3387-3390, 1994.
Gallo Pasquale
Monaci Paolo
Nuzzo Maurizio
Allen Marianne P
Finnegan Alysia A.
Heber Sheldon O.
Instituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
LandOfFree
Synthetic gene encoding human epidermal growth factor 2/neu... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic gene encoding human epidermal growth factor 2/neu..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic gene encoding human epidermal growth factor 2/neu... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4234530